⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of InnoMedica and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
InnoMedica
↗Bern, Switzerland
InnoMedica is a Swiss biopharmaceutical company specializing in the development of innovative nanomedicine-based drug delivery systems. By utilizing a proprietary, patent-protected liposomal technology platform, the company aims to enhance the targeted delivery and controlled release of active pharmaceutical ingredients, thereby improving therapeutic efficacy while reducing systemic side effects.
The company operates its own GMP-certified 'Nanofactory' in Marly, Switzerland, and maintains a diversified pipeline focused on oncology and neurodegenerative diseases. Key programs include Talidox (liposomal doxorubicin for cancer) and Tacurec (for Parkinson's disease), with clinical development activities spanning early-stage research through Phase II trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2000
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$83.1M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Liposomal Nanomedicine
Active Trials:0
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:InnoMedica Schweiz AG, InnoMedica Deutschland GmbH, YAMAZAKI-DDS Co., Ltd.
COMPETITION
Position:Niche Player
Competitors:Jazz Pharmaceuticals, Alnylam Pharmaceuticals, Spark Therapeutics
LEADERSHIP
Key Executives:
Peter Halbherr - Chairman and General Manager
Stéfan Halbherr - Head of Research & Development
Board Members:Peter Halbherr, Denis Bron, Noboru Yamazaki, Urs Wälchli
LINKS
Website:innomedica.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with InnoMedica. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.